Phase 4 N=200 Ciprofloxacin for Prevention of BK Infection
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=290 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
N/A N=40 Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK Viremia · BK Nephropathy
Primary: Number of Participants With BK Viral Load <600 Copies/mL — 13; 17 Participants
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=89 Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection
Renal Transplant Infection
Primary: Participants Will Experience Less BK Infection Episodes Based on Viruria Results.
Phase 4 N=10 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
N/A N=335 BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
BK Virus (BKV) Viremia
Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
Phase 1 N=16 Subcutaneous Abatacept in Renal Transplant Recipients
Kidney Transplant Recipient
Primary: Number of Participants Who Are Compliant With Self-administration — 8; 5; 1 Participants
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 2 N=40 Belatacept Post Depletional Repopulation to Facilitate Tolerance
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
N/A N=90 Vitamin D Replacement After Kidney Transplant
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 4 N=10 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
End-Stage Renal Disease · Hepatitis C
Primary: Number of Participants With Grade 3 or Higher Treatment-related Adverse Events as US Department of Health and Human Services Common Terminology of Adverse Events (CTCAE)…
Phase 4 N=40 Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
BK Virus Infection
Primary: Evidence of Reduction of BK Viruria and/or Clearance of BK Viremia — 11; 8 participants — p=0.53
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
N/A N=30 Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
N/A N=40 Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
Phase 2 N=32 Treg Therapy in Subclinical Inflammation in Kidney Transplantation
Kidney Transplant · Adult Living Donor Kidney Transplant Recipients · Renal Transplant
Primary: Incidence of Banff 2A or Higher Acute Cell-mediated Rejection and/or Acute Antibody Mediated Rejection — 0; 0; 0 Participants
Phase 2 N=62 Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
Phase 4 N=30 Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Phase 3 N=13 Belatacept Therapy for the Failing Renal Allograft
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
Phase 2 N=10 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Kidney Transplantation · Kidney Disease
Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events
Phase 4 N=30 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Renal Transplant Rejection · Immunosuppression
Primary: Cytokines Evaluation — 380; 893; 763; 147 MFI — p=<0.05
N/A N=30 DBS for Home Monitoring in Children With Kidney Transplantation
Kidney Disease
Primary: Variability of Tacrolimus Blood Levels Measured by DBS Over Time — 2.635 ng/ml
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
Phase 2 N=527 Calcineurin Inhibitor Sparing After Kidney Transplantation
CNI Side Effects
Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants